Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | MMP12 | P39900 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | MMP16 | P51512 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204495 | 0.81 | PTGS2 (0.56) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL3387728 | 0.80 | CXCL8 (0.41) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL7475089 | 0.79 | MIF (0.42) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL12318653 | 0.77 | GABRA1 (0.44) | PTGS1CYP3A4HPGDLMNAHIF1A | |
| SCHEMBL1343676 | 0.75 | PTGS2 (0.50) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL18797642 | 0.75 | PTGS2 (0.50) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL30717242 | 0.74 | PTGS2 (0.48) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL153695 | 0.74 | PTGS2 (0.59) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL27604135 | 0.74 | PTGS2 (0.48) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL362699 | 0.74 | PTGS2 (0.48) | PTGS2CXCL8MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| CN-113943312-A | Intestinal tract cracking type co-drug and preparation and application thereof | 轶诺(浙江)药业有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-20120094963-A1 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | of Queen Elizabeth near Dublin | 2012-04-19 | — | — | US | disclosed |
| WO-2010072734-A2 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2010-07-01 | — | — | WO | disclosed |
| EP-2160377-A1 | TARGETING DIAZO PRODRUGS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2010-03-10 | — | — | EP | disclosed |
| US-20090082314-A1 | Targeting Prodrugs for the Treatment of Gastrointestinal Diseases | THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE | 2009-03-26 | — | — | US | disclosed |
| WO-2009003970-A1 | TARGETING DIAZO PRODRUGS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082314-A1 | Targeting Prodrugs for the Treatment of Gastrointestinal Diseases | SI, NFKBIA, RELA | PTGS2 171/4885CXCL8 336/4885MMP2 1989/4885 |
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | PTGS2 655/4885CXCL8 255/4885MMP2 3959/4885 |
| US-20120094963-A1 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | PTGS2, SI, PTGS1 | PTGS2 1/4885CXCL8 2808/4885MMP2 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.